Growth Metrics

Merck (MRK) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 168.07%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -52.40%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -45.93%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -182.77%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 5.14%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 53.69%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 8.81%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -182.77%
Dec 31, 2025 -20.89%
Sep 30, 2025 83.07%
Jun 30, 2025 -18.92%
Mar 31, 2025 6.67%
Dec 31, 2024 405.38%
Sep 30, 2024 -33.45%
Jun 30, 2024 191.98%
Mar 31, 2024 68.74%
Dec 31, 2021 -111.85%
Jun 30, 2021 -49.77%
Mar 31, 2021 -86.42%
Dec 31, 2020 128.93%
Sep 30, 2020 -67.65%
Jun 30, 2020 -75.00%
Mar 31, 2020 12.47%
Dec 31, 2019 -201.69%
Sep 30, 2019 -2.60%
Jun 30, 2019 54.08%
Mar 31, 2019 286.23%
Dec 31, 2018 271.29%
Sep 30, 2018 3,939.22%
Jun 30, 2018 -12.05%
Mar 31, 2018 -52.38%
Dec 31, 2017 -76.83%
Sep 30, 2017 -102.33%
Jun 30, 2017 61.37%
Mar 31, 2017 37.70%
Dec 31, 2016 -159.78%
Sep 30, 2016 19.50%
Jun 30, 2016 75.73%
Mar 31, 2016 17.95%
Dec 31, 2015 -86.60%
Sep 30, 2015 117.46%
Jun 30, 2015 -66.16%
Mar 31, 2015 -44.66%
Dec 31, 2014 799.02%
Sep 30, 2014 -26.78%
Jun 30, 2014 117.43%
Mar 31, 2014 7.12%
Dec 31, 2013 154.55%
Sep 30, 2013 -34.77%
Jun 30, 2013 -48.63%
Mar 31, 2013 -8.55%
Dec 31, 2012 -69.20%
Sep 30, 2012 2.26%
Jun 30, 2012 -11.39%
Mar 31, 2012 227.67%
Dec 31, 2011 78.37%
Sep 30, 2011 182.75%
Jun 30, 2011 224.18%
Mar 31, 2011 34.29%
Dec 31, 2010 -137.05%
Sep 30, 2010 -536.79%
Jun 30, 2010 -361.30%
Mar 31, 2010 -362.34%